<p>Fate Therapeutics, Inc.（纳斯达克代码：FATE - 获取免费报告）在周二的交易中股价跌破了其 200 日移动平均线。该股票的 200 日移动平均线为 1.16 美元，最低交易价为 0.9510 美元。Fate Therapeutics 的股票最后交易价为 0.9768 美元，成交量为 3,583,512 股。</p>
<p>获取 <strong>Fate Therapeutics</strong> 的提醒：</p>
<h2>分析师评级上调和下调</h2>
<p>多家研究公司最近对 FATE 发布了报告。Needham &amp; Company LLC 在 10 月 27 日的报告中重申了对 Fate Therapeutics 股票的 “持有” 评级。Weiss Ratings 在 10 月 8 日的研究报告中重申了对 Fate Therapeutics 股票的 “卖出（e+）” 评级。HC Wainwright 在 10 月 31 日的研究报告中将 Fate Therapeutics 的股票评级从 “中性” 上调至 “买入”，并为该公司设定了 5.00 美元的目标价。Cantor Fitzgerald 在 11 月 4 日的研究报告中重申了对 Fate Therapeutics 股票的 “中性” 评级。最后，Wedbush 在 10 月 27 日的研究报告中将 Fate Therapeutics 的股票评级从 “中性” 上调至 “跑赢大盘”，并将该公司的目标价从 5.00 美元提高至 7.00 美元。三位股票研究分析师给予该股票 “买入” 评级，五位给予 “持有” 评级，一位给予 “卖出” 评级。根据 MarketBeat.com 的数据，Fate Therapeutics 目前的平均评级为 “持有”，共识目标价为 3.92 美元。</p>
<p><strong>查看我们对 FATE 的最新分析</strong></p>
<h2>Fate Therapeutics 股票表现</h2>
<p>该股票的 50 日移动平均价格为 1.18 美元，200 日移动平均价格为 1.16 美元。该公司的市值为 1.1267 亿美元，市盈率为-0.74，贝塔值为 2.34。</p>
<p>Fate Therapeutics（纳斯达克代码：FATE - 获取免费报告）于 11 月 13 日发布了季度财报。这家生物制药公司报告本季度每股收益为（-0.27 美元），超出分析师共识预期的（-0.29 美元）0.02 美元。Fate Therapeutics 的净利润率为-2,187.11%，股本回报率为-51.28%。该公司本季度的收入为 174 万美元，而共识预期为 163 万美元。卖方分析师预测 Fate Therapeutics, Inc.在本财年将发布每股收益-1.63 美元。</p>
<h2>对 Fate Therapeutics 的对冲基金看法</h2>
<p>几家对冲基金最近买入和卖出了 FATE 的股票。Savant Capital LLC 在第二季度收购了 Fate Therapeutics 的新头寸，价值 27,000 美元。Bridgeway Capital Management LLC 在第二季度购买了 Fate Therapeutics 的新头寸，价值 28,000 美元。Russell Investments Group Ltd.在第三季度将其在 Fate Therapeutics 的股份提高了 73.1%。Russell Investments Group Ltd.目前拥有 28,676 股该生物制药公司的股票，价值 36,000 美元，此前在上个季度又购买了 12,114 股。Headlands Technologies LLC 在第二季度购买了 Fate Therapeutics 的新股份，价值约 56,000 美元。最后，Caption Management LLC 在第一季度收购了 Fate Therapeutics 的新股份，价值约 45,000 美元。97.54% 的股票由对冲基金和其他机构投资者持有。</p>
<h2>关于 Fate Therapeutics</h2>
<p>（获取免费报告）</p>
<p>Fate Therapeutics, Inc 是一家临床阶段的生物制药公司，专注于开发首创的细胞免疫疗法，用于癌症和免疫疾病。该公司利用其专有的诱导多能干细胞（iPSC）平台，创建现成的自然杀伤（NK）细胞和 T 细胞产品，旨在克服供体来源方法的局限性。Fate 的研究旨在提供具有一致质量、增强效力和可扩展生产的疗法，以便广泛患者使用。</p>
<p>Fate 的研发管线的核心是多个处于积极临床开发中的 iPSC 衍生细胞疗法候选者。</p>
<h2>了解更多</h2>
<ul>
<li>我们更看好的五只股票比 Fate Therapeutics 更好</li>
<li>可能每月支付高达 4,290 美元的无聊 AI 投资</li>
<li>特朗普的 “美国房地产交易” 解释</li>
<li>在 1 月 1 日之前投资 1,000 美元于这只股票 [不是 NVDA]</li>
<li>警报：在 2026 年 1 月之前抛售这 5 只股票！</li>
<li>特朗普做了什么？？</li>
</ul>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或评论发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元于 Fate Therapeutics 吗？</h2>
<p>在你考虑 Fate Therapeutics 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只股票，顶级分析师正在悄悄地向客户推荐，现在买入，以便在更广泛的市场注意到之前……而 Fate Therapeutics 并不在名单上。</p>
<p>虽然 Fate Therapeutics 目前在分析师中获得 “持有” 评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>查看这五只股票</p>

FATE

<p>Fate Therapeutics 的股票跌破了 200 日移动平均线，最低交易价格为 0.9510 美元。分析师的评级各不相同：三位买入，五位持有，一位卖出。该股票的平均评级为持有，目标价格为 3.92 美元。最近的财报超出预期，报告每股亏损 0.27 美元。对冲基金正在积极交易该股票，持股比例为 97.54%。Fate Therapeutics 专注于癌症和免疫疾病的细胞免疫疗法</p>

<p>Fate Therapeutics, Inc. (NASDAQ:FATE - Get Free Report) shares crossed below its 200-day moving average during trading on Tuesday . The stock has a 200-day moving average of $1.16 and traded as low as $0.9510. Fate Therapeutics shares last traded at $0.9768, with a volume of 3,583,512 shares changing hands.</p>
<div class="lb-trans"><p>Fate Therapeutics, Inc.（纳斯达克代码：FATE - 获取免费报告）在周二的交易中股价跌破了其 200 日移动平均线。该股票的 200 日移动平均线为 1.16 美元，最低交易价为 0.9510 美元。Fate Therapeutics 的股票最后交易价为 0.9768 美元，成交量为 3,583,512 股。</p>
</div><p>Get <strong>Fate Therapeutics</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Fate Therapeutics</strong> 的提醒：</p>
</div><h2>Analyst Upgrades and Downgrades</h2>
<div class="lb-trans"><h2>分析师评级上调和下调</h2>
</div><p>A number of research firms have recently issued reports on FATE. Needham &amp; Company LLC reissued a &#34;hold&#34; rating on shares of Fate Therapeutics in a report on Monday, October 27th. Weiss Ratings restated a &#34;sell (e+)&#34; rating on shares of Fate Therapeutics in a research report on Wednesday, October 8th. HC Wainwright upgraded shares of Fate Therapeutics from a &#34;neutral&#34; rating to a &#34;buy&#34; rating and set a $5.00 target price for the company in a research note on Friday, October 31st. Cantor Fitzgerald reiterated a &#34;neutral&#34; rating on shares of Fate Therapeutics in a research note on Tuesday, November 4th. Finally, Wedbush upgraded shares of Fate Therapeutics from a &#34;neutral&#34; rating to an &#34;outperform&#34; rating and raised their price objective for the company from $5.00 to $7.00 in a research report on Monday, October 27th. Three equities research analysts have rated the stock with a Buy rating, five have assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, Fate Therapeutics presently has an average rating of &#34;Hold&#34; and a consensus price target of $3.92.</p>
<div class="lb-trans"><p>多家研究公司最近对 FATE 发布了报告。Needham &amp; Company LLC 在 10 月 27 日的报告中重申了对 Fate Therapeutics 股票的 “持有” 评级。Weiss Ratings 在 10 月 8 日的研究报告中重申了对 Fate Therapeutics 股票的 “卖出（e+）” 评级。HC Wainwright 在 10 月 31 日的研究报告中将 Fate Therapeutics 的股票评级从 “中性” 上调至 “买入”，并为该公司设定了 5.00 美元的目标价。Cantor Fitzgerald 在 11 月 4 日的研究报告中重申了对 Fate Therapeutics 股票的 “中性” 评级。最后，Wedbush 在 10 月 27 日的研究报告中将 Fate Therapeutics 的股票评级从 “中性” 上调至 “跑赢大盘”，并将该公司的目标价从 5.00 美元提高至 7.00 美元。三位股票研究分析师给予该股票 “买入” 评级，五位给予 “持有” 评级，一位给予 “卖出” 评级。根据 MarketBeat.com 的数据，Fate Therapeutics 目前的平均评级为 “持有”，共识目标价为 3.92 美元。</p>
</div><p><strong>Check Out Our Latest Analysis on FATE</strong></p>
<div class="lb-trans"><p><strong>查看我们对 FATE 的最新分析</strong></p>
</div><h2>Fate Therapeutics Stock Performance</h2>
<div class="lb-trans"><h2>Fate Therapeutics 股票表现</h2>
</div><p>The stock's fifty day moving average price is $1.18 and its 200-day moving average price is $1.16. The firm has a market cap of $112.67 million, a PE ratio of -0.74 and a beta of 2.34.</p>
<div class="lb-trans"><p>该股票的 50 日移动平均价格为 1.18 美元，200 日移动平均价格为 1.16 美元。该公司的市值为 1.1267 亿美元，市盈率为-0.74，贝塔值为 2.34。</p>
</div><p>Fate Therapeutics (NASDAQ:FATE - Get Free Report) last released its quarterly earnings data on Thursday, November 13th. The biopharmaceutical company reported ($0.27) EPS for the quarter, topping analysts' consensus estimates of ($0.29) by $0.02. Fate Therapeutics had a negative net margin of 2,187.11% and a negative return on equity of 51.28%. The firm had revenue of $1.74 million for the quarter, compared to the consensus estimate of $1.63 million. Sell-side analysts forecast that Fate Therapeutics, Inc. will post -1.63 earnings per share for the current fiscal year.</p>
<div class="lb-trans"><p>Fate Therapeutics（纳斯达克代码：FATE - 获取免费报告）于 11 月 13 日发布了季度财报。这家生物制药公司报告本季度每股收益为（-0.27 美元），超出分析师共识预期的（-0.29 美元）0.02 美元。Fate Therapeutics 的净利润率为-2,187.11%，股本回报率为-51.28%。该公司本季度的收入为 174 万美元，而共识预期为 163 万美元。卖方分析师预测 Fate Therapeutics, Inc.在本财年将发布每股收益-1.63 美元。</p>
</div><h2>Hedge Funds Weigh In On Fate Therapeutics</h2>
<div class="lb-trans"><h2>对 Fate Therapeutics 的对冲基金看法</h2>
</div><p>Several hedge funds have recently bought and sold shares of FATE. Savant Capital LLC acquired a new position in Fate Therapeutics during the second quarter worth $27,000. Bridgeway Capital Management LLC purchased a new position in shares of Fate Therapeutics in the second quarter valued at $28,000. Russell Investments Group Ltd. raised its stake in shares of Fate Therapeutics by 73.1% during the 3rd quarter. Russell Investments Group Ltd. now owns 28,676 shares of the biopharmaceutical company's stock worth $36,000 after buying an additional 12,114 shares during the last quarter. Headlands Technologies LLC purchased a new stake in shares of Fate Therapeutics in the 2nd quarter worth about $56,000. Finally, Caption Management LLC acquired a new stake in Fate Therapeutics in the 1st quarter valued at about $45,000. 97.54% of the stock is owned by hedge funds and other institutional investors.</p>
<div class="lb-trans"><p>几家对冲基金最近买入和卖出了 FATE 的股票。Savant Capital LLC 在第二季度收购了 Fate Therapeutics 的新头寸，价值 27,000 美元。Bridgeway Capital Management LLC 在第二季度购买了 Fate Therapeutics 的新头寸，价值 28,000 美元。Russell Investments Group Ltd.在第三季度将其在 Fate Therapeutics 的股份提高了 73.1%。Russell Investments Group Ltd.目前拥有 28,676 股该生物制药公司的股票，价值 36,000 美元，此前在上个季度又购买了 12,114 股。Headlands Technologies LLC 在第二季度购买了 Fate Therapeutics 的新股份，价值约 56,000 美元。最后，Caption Management LLC 在第一季度收购了 Fate Therapeutics 的新股份，价值约 45,000 美元。97.54% 的股票由对冲基金和其他机构投资者持有。</p>
</div><h2>About Fate Therapeutics</h2>
<div class="lb-trans"><h2>关于 Fate Therapeutics</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Fate Therapeutics, Inc is a clinical‐stage biopharmaceutical company focused on the development of first‐in‐class cellular immunotherapies for cancer and immune disorders. The company leverages its proprietary induced pluripotent stem cell (iPSC) platform to create off‐the‐shelf natural killer (NK) and T‐cell products designed to overcome limitations of donor‐derived approaches. Fate's research aims to deliver therapies with consistent quality, increased potency and scalable manufacturing for broad patient access.</p>
<div class="lb-trans"><p>Fate Therapeutics, Inc 是一家临床阶段的生物制药公司，专注于开发首创的细胞免疫疗法，用于癌症和免疫疾病。该公司利用其专有的诱导多能干细胞（iPSC）平台，创建现成的自然杀伤（NK）细胞和 T 细胞产品，旨在克服供体来源方法的局限性。Fate 的研究旨在提供具有一致质量、增强效力和可扩展生产的疗法，以便广泛患者使用。</p>
</div><p>Central to Fate's pipeline are multiple iPSC‐derived cell therapy candidates in active clinical development.</p>
<div class="lb-trans"><p>Fate 的研发管线的核心是多个处于积极临床开发中的 iPSC 衍生细胞疗法候选者。</p>
</div><h2>Read More</h2>
<div class="lb-trans"><h2>了解更多</h2>
</div><ul>
<li>Five stocks we like better than Fate Therapeutics</li>
<li>The boring AI play that could pay up to $4,290 monthly</li>
<li>Trump’s “real estate deal for America” explained</li>
<li>Put $1,000 into this stock by Jan 1 [Not NVDA]</li>
<li>ALERT: Drop these 5 stocks before January 2026!</li>
<li>Trump Did WHAT??</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票比 Fate Therapeutics 更好</li>
<li>可能每月支付高达 4,290 美元的无聊 AI 投资</li>
<li>特朗普的 “美国房地产交易” 解释</li>
<li>在 1 月 1 日之前投资 1,000 美元于这只股票 [不是 NVDA]</li>
<li>警报：在 2026 年 1 月之前抛售这 5 只股票！</li>
<li>特朗普做了什么？？</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或评论发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Fate Therapeutics Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元于 Fate Therapeutics 吗？</h2>
</div><p>Before you consider Fate Therapeutics, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考虑 Fate Therapeutics 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Fate Therapeutics wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只股票，顶级分析师正在悄悄地向客户推荐，现在买入，以便在更广泛的市场注意到之前……而 Fate Therapeutics 并不在名单上。</p>
</div><p>While Fate Therapeutics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Fate Therapeutics 目前在分析师中获得 “持有” 评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看这五只股票</p>
</div>

Fate Therapeutics（NASDAQ:FATE）的股票跌破了两百日移动平均线 - 接下来会发生什么？